Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) Equity Ratio: 2019-2025

Historic Equity Ratio for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to 0.71.

  • Revolution Medicines' Equity Ratio fell 20.18% to 0.71 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.71, marking a year-over-year decrease of 20.18%. This contributed to the annual value of 0.89 for FY2024, which is 0.04% down from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Equity Ratio is 0.71, which was down 7.64% from 0.77 recorded in Q2 2025.
  • Revolution Medicines' Equity Ratio's 5-year high stood at 0.90 during Q1 2024, with a 5-year trough of 0.71 in Q3 2025.
  • Moreover, its 3-year median value for Equity Ratio was 0.89 (2024), whereas its average is 0.86.
  • As far as peak fluctuations go, Revolution Medicines' Equity Ratio climbed by 11.44% in 2021, and later decreased by 20.18% in 2025.
  • Revolution Medicines' Equity Ratio (Quarterly) stood at 0.82 in 2021, then grew by 3.36% to 0.84 in 2022, then grew by 4.96% to 0.89 in 2023, then fell by 0.04% to 0.89 in 2024, then decreased by 20.18% to 0.71 in 2025.
  • Its Equity Ratio was 0.71 in Q3 2025, compared to 0.77 in Q2 2025 and 0.88 in Q1 2025.